Five Prime Therapeutics Stock Analysis (NASDAQ:FPRX)

Add to My Stocks
$34.42 $0.36 (1.06%) FPRX stock closing price Apr 25, 2017 (Closing)
Watch Robo Advisor Video of FPRX Stock Analysis
Five Prime Therapeutics
Updated on : Apr 25, 2017
previous close
FPRX 34.4 (0%)
S&P 500 2388.6 (0%)
Closing Price On: Apr 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-323.3%
Sector Average:
0.6%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Cash Flow
Operating cash flow:
-$14.9M
Net Income:
-$20.1M
PROS      CONS
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
FPRX PS :
30.8
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-15.8%
Free Cash Flow Margin:
-190.8%
Double Tap To Exit Full Screen
0:00
/

Five Prime Therapeutics Analysis Video

125 5 2

View Five Prime Therapeutics stock analysis video. This is our FPRX analyst opinion covering the buy and sell arguments for FPRX stock.

Five Prime Therapeutics Inc Stock Rating (1.9/5)

Our Five Prime Therapeutics stock opinion is based on fundamentals of the company. This Five Prime Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy FPRX stock?

Should you sell FPRX stock?

  • Five Prime Therapeutics reported an average operating margin of -323.3% over the Last Twelve Months (LTM).
  • Five Prime Therapeutics posted an average Net loss of -214.1% in the last twelve months.
  • The lack of profits renders the PE ratio useless for FPRX stock.
  • FPRX stock is trading at a PS multiple of 30.8, which is a negative when compared to the Medical-Biomed-Genetics industry average multiple of 4.7.
  • A negative ROE of -15.8% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -190.8%.

Comments on this video and Five Prime Therapeutics stock